Reproductive health startup raises $65M for infertility drugs
ReproNovo, a biotechnology company specializing in reproductive medicine, has raised $65 million to advance two drugs it thinks could help address fertility issues in men and women.
The Switzerland-based firm plans to use the new funds to run Phase 2 clinical trials of the drugs. The first, called leflutrozole, is designed to treat infertility in men with low testosterone, while the second, nolasiban, will be studied in women with a gynecological disorder called adenomyosis and as an adjunctive therapy alongside assisted reproductive technologies.
'We are here to fill the critical gaps for patients in reproductive medicine and women's health,' Jean Maire Duvall, CEO and co-founder of ReproNovo, told BioPharma Dive.
Founded in 2021, ReproNovo gained rights to the candidates through licensing deals with Mereo BioPharma and ObsEva, respectively.
Leflutrozole is a small molecule that works by blocking an enzyme called aromatase. This effect, ReproNovo says, could help stabilize levels of testosterone and address male infertility. Some research has raised concerns about declines in male reproductive health, as fertility rates among women in the U.S. have also fallen.
Although infertility impacts both men and women, the pressure and responsibility for solving the issue often falls on the woman. 'We'd like to offer an alternative where the male could be treated directly,' said Duvall.
Nolasiban blocks oxytocin receptors, which ReproNovo sees as potentially helpful in managing adenomyosis, a condition where endometrial tissue grows in the uterine walls. Adenomyosis can cause similar symptoms as endometriosis, such as pelvic pain and heavy menstrual bleeding. The condition often occurs in women between the ages of 35 to 50. There are no drugs specifically approved to treat it.
ReproNovo is also studying whether nolasiban can improve embryo implantation by reducing uterine contractility and enhancing blood flow amid embryo transfer during in vitro fertilization. While other treatments are available and in development to increase the chances of IVF success, none are approved to support embryo implantation specifically, the company said.
The Series A funding round was led by Jeito Capital and co-led by AXA IM Alts and ReproNovo's founding investor M Ventures, the venture arm of Merck KGaA. Ysios Capital and Alsa Ventures also participated.
Recommended Reading
Women's health faces growing headwinds, despite jump in venture investment
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Calls for ‘landscape-wide' action to protect butterflies amid falling numbers
Conservationists have called for 'landscape-wide' action to protect butterflies, as new official figures indicate declines of nearly a fifth since the 1970s. The latest annual update on butterfly monitoring published by the Environment Department (Defra) reveal abundance across all butterfly species has declined 18% in the UK and 19% in England over the long-term. The situation is even worse for specialists which need specific habitats such as flower-rich grassland, heathland and woodland clearings to thrive, with numbers declining by more than a third (39%) across the UK, and 25% in England. And some individual species of butterflies have seen numbers plummet by more than 80% since 1976, the monitoring suggests. Conservationists warn falls in the abundance of butterflies are a signal of problems in the wider environment, and reveal what is happening to many other insects that are a key part of ecosystems. The latest figures include 2024, which wildlife charity Butterfly Conservation's head of science Dr Richard Fox described as a 'terrible year for the UK's butterflies'. May last year was the warmest on record, but had notably low levels of sunshine, and overall 2024 ranked as the fourth warmest and eighth wettest year since the early 1900s, disrupting seasonal patterns essential to many butterfly species. The weather conditions hit butterflies which were already struggling with habitat loss and pollution, conservationists warn. Dr Fox said: 'With the addition of data from 2024, which was a terrible year for the UK's butterflies, these updated indicators reiterate the long-term decline of these beautiful insects. 'In particular, habitat specialists – butterfly species that rely on specific habitats such as heathland, woodland clearings or flower-rich grassland – have fared poorly since the 1970s as humans have destroyed and polluted these habitats. 'When we also factor in the implications of climate change, which is resulting in unpredictable extremes of weather, it is more important than ever that we take conservation action on a landscape-wide scale.' The data indicate nearly half (46%) of individual species that are restricted to certain habitats have seen declines in the UK, while 50% have seen numbers fall in England. Across the UK, heath fritillary has seen the most severe declines since 1976 with an 89% drop in abundance, while other habitat specialists including wood white, small-bordered fritillary, grayling and pearl-bordered fritillary have seen declines of 70% to 80%. The assessment from Defra said the main causes for the declines in habitat specialist butterflies were the loss, fragmentation and degradation of those landscapes, with more intensive agriculture also contributing to the drop in numbers. Many have not recovered from declines experienced in the late 1970s, which were partly as a result of the knock-on effects of the drought conditions in 1976, but a lack of suitable habitat after that is the main driver for persistent declines and lack of recovery since, it said. Butterflies found on farmland have declined by around a third in both the UK and England, with those that require the specific habitat to thrive seeing falls in abundance of 42% in the UK and 47% in England. Woodland butterflies have fared even worse with declines of more than half (54%) since the 1970s when monitoring began, with woodland specialist species declining by 55% in the UK and 57% in England. Butterflies have also seen short-term declines on farmland, with numbers falling 12% across the UK and 11% in England over the past decade, the figures suggest, while woodland butterflies have shown no significant change over the same period. But the findings also indicate some specialist species are on the increase, including black hairstreak, silver-spotted skippers, large heath, dark green fritillary, silver-washed fritillary and purple emperor. Officials said some recent increases could be attributed to targeted conservation action, while some species are benefiting from climate change which is allowing them to expand their range. Dr Fox urged: 'Looking at the specific conditions these species need to thrive and working to reinstate them where we can will offer some of these very vulnerable species an opportunity to recover.' Across more 'generalist' species, which are not restricted to specific habitats, there has been no change over the long or short-term, but the fortunes of individual species have differed wildly. Small tortoiseshell butterflies have seen falls of 86% between 1976 and 2024, while wall and white-letter hairstreak butterflies have seen almost as severe declines. But ringlet butterflies have increased by 273%, and holly blue and comma butterflies have also seen some of the largest increases in abundance over five decades, the figures suggest. Across the 50 species monitored across the UK, 44% have suffered declines since 1976, while 47% of the 49 species assessed in England have seen drops since then. Some 28% of individual species have increased across the UK and 24% have increased in England, the statistics indicate.
Yahoo
2 hours ago
- Yahoo
Coloplast A/S – Updated presenters list for Capital Markets Day on 2 September 2025
Following the changes to the Executive Leadership Team, announced on 19.08.2025*, we are pleased to share with you the updated presenters list for our Capital Markets Day on 2 September 2025. For those of you who have signed up, we look forward to seeing you at the event. The event will take place on Tuesday, 2 September 2025 at Clarion Hotel (Copenhagen airport)Ellehammersvej 20, 2770 Kastrupfrom 10.30 - 17.00 CEST(Central European Summer Time) The event will be held in person at Clarion Hotel in Copenhagen, Denmark, with the option to join virtually for the plenary session. A link for the webcast of the plenary sessions will be available on our website closer to the date. The purpose of the event is to give institutional investors and financial analysts an introduction to the new 5-year strategy for the company, as well as to provide the opportunity to meet with the broader Management team. The day will start with a plenary session, covering the introduction of the new Group strategy, a financial update, and the strategy for the Chronic Care businesses. In the afternoon, participants will be split into groups and rotate between four Q&A breakout sessions. Participation in the breakout sessions will be in-person only (with a replay of the presentations available after the event). The formal program will end at 17.00, followed by an opportunity to meet the Coloplast management team in an informal setting. Agenda in CEST10.00 - 10.30 Registration10.30 - 12.30 Plenary session: Group strategy and financials, Chronic Care Commercial strategy12.30 - 13.00 Lunch break13.00 - 17.00 Q&A breakout sessions (incl. breaks)17.00 - 18.30 Social activity (on premise) Coloplast representatives Plenary session: Lars Rasmussen, Interim President and CEO Anders Lonning-Skovgaard, Executive Vice President, CFO Caroline Vagner Rosenstand, Executive Vice President, Chronic Care Commercial Breakout sessions: Chronic Care deep dive: Mike DelVacchio, Senior Vice President, North America Thomas Bruhn, Senior Vice President, Emerging Markets Wound & Tissue Repair: Fertram Sigurjonsson, Executive Vice President, Wound & Tissue Repair Bernd Greiner, Senior Vice President, Adv. Wound Dressings Interventional Urology: Thomas NP Johns Jr, Executive Vice President, Interventional Urology Global Operations and People & Culture: Allan Rasmussen, Executive Vice President, Global Operations Dorthe Rønnau, Executive Vice President, People & Culture * For more information,please contact: Aleksandra Dimovska, Vice PresidentDirect tel.: +45 4911 2458E-mail: dkadim@ Kristine Husted Munk, Sr. ManagerDirect tel.: +45 4911 3266E-mail: dkkhu@ Simone Dyrby Helvind, Sr. Manager Direct tel.: +45 4911 2981E-mail: dksdk@ Julie Sommer Müggler, Coordinator Direct tel.: +45 4911 3161Email: dkjusm@ Attachment Updated presenters list Coloplast CMD 2025
Medscape
3 hours ago
- Medscape
Can Weight Loss Boost Pregnancy Rates?
A 10%-25% weight loss can help women considered overweight or having obesity become pregnant — even if they weren't trying to conceive — and reduce their chances for some pregnancy-related conditions and complications, according to a new study on reproduction. The study included patient data from nearly 250,000 women in the UK aged 18-40 years who had a BMI ≥ 25, which is considered overweight. BMI measures an estimate of body fat based on height and weight. Patients with obesity, who have a BMI ≥ 30, were also part of the study. Women in these categories who dropped the weight with a median loss of 14% had a small increase, about 5%, of becoming pregnant in the following 3 years compared with those with stable weight, according to the study published in Human Reproduction by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. The study used patient data collected from primary care practices linked to hospital records in England between January 2000 and May 2022. Nearly 80% of the women in the study kept a stable weight and the rest lost weight. Of the women who became pregnant (9%), those who lost weight had a 'statistically significant reduction' in the risk for gestational diabetes and emergency caesarean section, the study found. The women who lost weight also saw reduced pregnancy-induced hypertension with fewer babies born considered large for their gestational age compared with women of stable weight. Novo Nordisk — the maker of weight-loss drug Wegovy and diabetes drug Ozempic — funded the study, and most of the study authors work for the pharmaceutical company and/or hold shares or stock. Medscape Medical News asked a few clinicians, including Ob/Gyns with specialized training to treat patients with obesity, to weigh in on the study's findings. 'There is a lot of data to support that women that have obesity or are overweight have higher risks in their pregnancy but also have a more difficult time conceiving,' said Deidre Neyhart-McIntosh, MD, an Ob/Gyn with the Cleveland Clinic, Cleveland, who is trained in obesity medicine. The study shows that the healthier a woman can be prior to conceiving, the easier it will likely be for her to conceive and have a more successful pregnancy, McIntosh said. In her practice, McIntosh has seen that women who lose even 5% of their body weight can reduce their blood pressure, glucose, lipids, inflammation, and cardiovascular risk. McIntosh said she speaks with patients who want to be pregnant about the risks of having obesity, such as diabetes, hypertension, preeclampsia, pre-term delivery, or caesarian section of a large baby. She advises women to try to lose weight 6 months before they want to become pregnant and to study the habits that help them lose weight to continue eating healthy during pregnancy. Patients who are overweight may seek her help if they have difficulty becoming pregnant or have risk factors such as high blood pressure or prediabetes, she said. In those cases, McIntosh might discuss nutrition, exercise, or prescribe weight-loss medicine to help them improve their chances of a healthy pregnancy. McIntosh finds that most of her patients have tried other methods to lose weight before requesting weight-loss medicine. Depending on the medication, they should stop the drugs either immediately prior to conceiving or 2 months beforehand. Despite the study's connection to a weight-loss drug maker, McIntosh said she still believes the findings are valid. 'Obviously, we're going to pick out some of the biases, but overall, they looked at a wide variety of women and didn't focus on women that were just taking weight-loss medications either,' she said. Weight-Loss Medications The FDA has approved some of the newer medications for chronic weight management in adults with obesity, or if they are overweight, with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Johanna Finkle, MD, an Ob/Gyn and weight-loss specialist with the University of Kansas Health System, Kansas City, Kansas, said that although the study doesn't specifically mention weight-loss drugs, a weight loss of 10%-25% is typically only seen in women taking the medicine for weight loss. From her experience, diet and exercise only produce a 3%-5% weight loss in a year, Finkle said. The study also cited previous research with different diets and exercise that didn't show decreased pregnancy complications or increased spontaneous conception, she noted. Finkle believes the new study looked at weight loss because women are losing significant weight on the medicines Novo Nordisk manufactures, namely GLP-1 receptor agonists. 'The question that they are trying to answer: Is this going to be beneficial to a preconception population and how much weight loss [is optimal] because these drugs are producing more weight loss than we see with diet and exercise alone,' she said. Optimal Weight Loss 'Right now, what we counsel is about 10% weight loss of body weight prior to pregnancy,' Finkle said. 'Any weight loss may be beneficial.' There are also risks to losing too much weight, especially in patients losing 30% of their body weight, she said. 'What I'm seeing in my patients is sometimes they're not consuming enough calories or even enough water,' Finkle said. 'I'm having to remind them that they need to eat more frequently. We discuss sufficient protein.' Others may experience hair loss. When patients lose a significant amount of weight, it can affect pregnancy. Patients who went through bariatric surgery have a risk for preterm delivery, Finkle said. 'I worry about small-for-gestational-age babies and an increased risk for miscarriage when people have a rapid trajectory of weight loss,' she said. Finkle said she counsels patients who are rapidly losing weight to try not to conceive while on the medication because 'the data on teratogenic risk of the weight-loss medications is not yet known.' Ideally, patients who want to lose weight before they conceive should come to her a year in advance, Finkle said. 'But if they're wanting to conceive in 3 months, then we discuss healthy behaviors, lifestyle, nutrition, and exercise counseling. We discuss: What is your goal? When do you want to conceive and how does weight loss play a role in that? How much weight loss can we achieve?' she said. Research Implications While previous research may have focused on the outcomes of women undergoing fertility treatment, the Novo Nordisk study wasn't restricted to women trying to conceive, so study authors said that the benefits of weight loss may be greater in women who are actively trying to become pregnant. Erin LeBlanc, MD, who conducts similar research about weight loss and pregnancy, believes the Novo Nordisk study provides further evidence that women having trouble becoming pregnant because they are overweight or have obesity could benefit from weight loss. In other words, if having a higher BMI is associated with decreased fertility rates, weight loss among that population could have the opposite impact, she said. LeBlanc, an epidemiologist and endocrinologist with the Kaiser Permanente Center for Health Research, said the Novo Nordisk study also aligns with research she led showing that women who lost weight had lower rates of gestational diabetes in early pregnancy. Because some women in the clinical trial gained weight back later in pregnancy, she stressed the importance of weight management throughout pregnancy. Women in her study who met with health coaches weekly for 6 months and then monthly for 18 months or until the end of their pregnancy were able to start pregnancy at a healthier weight. However, they experienced more weight gain during pregnancy, likely because it was challenging to maintain the healthy lifestyle changes they made prepregnancy without ongoing support, she said of the study originally published in 2021 in the American Journal of Obstetrics & Gynecology. ' What I would say from my research is that if women have been able to lose weight before pregnancy, they just need to be sure that they get support during pregnancy to help them to maintain a healthy lifestyle,' LeBlanc said. LeBlanc also said the new study may help inform future recommendations from the National Academy of Medicine, formerly the Institute of Medicine, which advised in 2009 that women achieve a healthy weight before becoming pregnant and remain within the gestational weight gain guidelines during pregnancy. Women with a healthy weight should gain 25-35 pounds; women who are overweight, 15-25 pounds; and women with obesity, 11-20 pounds, according to those guidelines. Study Limitations Among the limitations of the study, Finkle said using participants from the UK cannot necessarily be applied to those from the US. 'They did not cite the composition of their patient population,' she said. 'The United States is very diverse.' Finkle said that the median age of the patients (30 years) is also important to note. 'When you are talking about fertility, age plays a much larger role than necessarily body weight when looking at someone's ability to conceive.' Study authors said they didn't know whether women had intended to become pregnant or whether that intention was why they lost weight. Including women who don't intend to conceive may also affect the findings by underestimating the relationship between weight loss and chance of pregnancy, the authors said. And while they observed a link between weight loss and increased chance of pregnancy, they said they couldn't imply higher pregnancy rates were caused by weight loss. In her practice, Finkle often sees patients trying to lose weight prior to conception. 'So if more patients in the group that was actually trying to lose weight wanted to conceive, they're going to have higher rates of pregnancy than a weight stable group that maybe wasn't trying or had any intention of conceiving and were using maybe other methods to prevent pregnancy,' she said. Overall, Finkle found promising the study's finding of a small increase in conception from weight loss. She said more studies are needed to look at weight loss and pregnancy, including how weight gain during pregnancy affects the delivery and health of the mother and child. 'There's this phenomenon called weight cycling,' Finkle said. 'You may lose weight, then regain the same — or more — during pregnancy, and the question becomes: How will that affect outcomes such as large-for-gestational-age babies, cesarean-section deliveries, or hypertensive disorders? Many questions remain unanswered.'
